Lack of MHC restriction enables applicability to patients expressing surface TAAs regardless of MHC allele expression.Efficient depletion of hematologic cancer.Off-target ‘bystander’ killing of antigen-negative tumor cells. This evidence concerns the gene HLA-C and neoplasm.